Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults ...

Lumina AI is proud to announce that Ben Martin and Sam Martin, co-inventors of RCL with Dr. Morten Middelfart, are rejoining the company as AI Research Scientists to support its next phase of growth.

Half-Year Results and Business UpdatePositive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% ...

Stochastic dynamical systems arise in many scientific fields, such as asset prices in financial markets, neural activity in ...

Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...

Dr. Allison Winter secured a VeloSano grant after five years of rejected proposals for central nervous system lymphoma ...

The CORE-MD (Coordinating Research and Evidence for high-risk Medical Devices) consortium has published new consensus ...

Sacubitril/valsartan shows evidence of benefit in the first randomized trial evaluating a drug treatment for patients with ...

Some feel the guidance may encourage consistent follow-up of overall survival after accelerated approvals, but others remain focused on speeding new drugs to patients.

Results of a new study support using semaglutide and tirzepatide to reduce risk in patients with cardiometabolic heart failure with preserved ejection fraction.The study investigated the effectiveness ...

RAAINBOW Phase 2/3 Paediatric Alopecia Areata Trial Featuring CliniExperts Research Services Published in British Journal of ...